Xiaobin Lu
20 Papers
449 Citations
Xiaobin Lu is an academic researcher. The author has contributed to research in topics: Viral vector & Transduction (genetics). The author has an hindex of 9, co-authored 20 publications.
Chat about Author
Papers
Gene transfer in humans using a conditionally replicating lentiviral vector
Bruce L. Levine,Laurent Humeau,Jean D. Boyer,Rob-Roy MacGregor,Tessio Rebello,Xiaobin Lu,Gwendolyn K. Binder,Vladimir Slepushkin,Franck Lemiale,John R. Mascola,Frederic D. Bushman,Boro Dropulic,Carl H. June +12 more
TL;DR: Lentiviral vectors appear promising for gene transfer to humans and there is no evidence for insertional mutagenesis after 21–36 months of observation.
Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector.
Peter Manilla,Tessio Rebello,Cathleen Afable,Xiaobin Lu,Vladimir Slepushkin,Laurent Humeau,Kathy Schonely,Yajin Ni,Gwendolyn K. Binder,Bruce L. Levine,Rob-Roy MacGregor,Carl H. June,Boro Dropulic +12 more
TL;DR: This review provides an overview of the major safety concerns regarding insertional oncogenesis, the generation of a replication- competent lentivirus (RCL), and vector mobilization thought to be related to lentiviral vectors, which had to be addressed during the regulatory review process before initiating the clinical trial.
165
Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load.
Laurent Humeau,Gwendolyn K. Binder,Xiaobin Lu,Vladimir Slepushkin,Randall K. Merling,Patricia Echeagaray,Mario Pereira,Tatiana Slepushkina,Scott Barnett,Lesia K. Dropulic,Richard G. Carroll,Bruce L. Levine,Carl H. June,Boro Dropulic +13 more
TL;DR: It is demonstrated that VRX496T therapy is expected to be beneficial to patients that differ in their status in term of CD4 count and viral load, and is currently being employed in the first trial evaluating lentivirus vector safety in humans.
138
Antisense-Mediated Inhibition of Human Immunodeficiency Virus (HIV) Replication by Use of an HIV Type 1-Based Vector Results in Severely Attenuated Mutants Incapable of Developing Resistance
Xiaobin Lu,Yu Qiao,Gwendolyn K. Binder,Ziping Chen,Tatiana Slepushkina,John J. Rossi,Boro Dropulic +6 more
TL;DR: It is demonstrated for the first time that during antisense-mediated suppression of HIV, mutants develop as a direct result of selective pressure on the HIV genomic RNA.
107
Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol.
Xiaobin Lu,Laurent Humeau,Vladimir Slepushkin,Gwendolyn K. Binder,Yu Qiao,Tatiana Slepushkina,Ziping Chen,Randall K. Merling,Brian Davis,Chang Yung-Nien,Boro Dropulic +10 more
TL;DR: It is demonstrated that there is no significant in vivo vector mobilization using a primary SCID‐hu mouse transplantation model, which correlates with the presence of an anti‐HIV payload and suggests that inclusion of antisense may be a useful tool to restrict mobilization in other vector constructs.
80